{"transactions":[{"id":758452,"issuer":{"id":6560,"kind":"organization","name":"Equillium, Inc."},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-05-29T22:25:11.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing on the grant date of May 28, 2026, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date."}],"balance_after":70000,"derivative":{"exercise_price":2.84,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001559569-26-000001","document":"form4-05292026_100506.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1559569/000155956926000001/form4-05292026_100506.xml","form_type":"4"}},{"id":1134813,"issuer":{"id":6560,"kind":"organization","name":"Equillium, Inc."},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-23T17:45:29.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing on the grant date of May 21, 2025, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date."}],"balance_after":20000,"derivative":{"exercise_price":0.39,"expiration_date":"2035-05-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-25-014398","document":"form4-05232025_050525.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1559569/000141588925014398/form4-05232025_050525.xml","form_type":"4"}},{"id":1258761,"issuer":{"id":6560,"kind":"organization","name":"Equillium, Inc."},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-02-20T00:39:20.000Z","date":"2025-02-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023.  All of the other terms of the options remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests in twelve equal monthly installments commencing on the grant date of May 24, 2022, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date."}],"balance_after":0,"derivative":{"exercise_price":2.59,"expiration_date":"2032-05-23","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-25-004759","document":"form4-02202025_120216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1559569/000141588925004759/form4-02202025_120216.xml","form_type":"4"}},{"id":1258760,"issuer":{"id":6560,"kind":"organization","name":"Equillium, Inc."},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-02-20T00:39:20.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023.  All of the other terms of the options remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests in twelve equal monthly installments commencing on the grant date of May 24, 2022, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date."}],"balance_after":20000,"derivative":{"exercise_price":0.785,"expiration_date":"2032-05-23","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-25-004759","document":"form4-02202025_120216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1559569/000141588925004759/form4-02202025_120216.xml","form_type":"4"}},{"id":1258759,"issuer":{"id":6560,"kind":"organization","name":"Equillium, Inc."},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-02-20T00:39:20.000Z","date":"2025-02-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20770,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023.  All of the other terms of the options remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options vest in twelve equal monthly installments commencing on the grant date of May 26, 2021, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date."}],"balance_after":0,"derivative":{"exercise_price":6.55,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":20770},"source":{"system":"sec-edgar","filing":"0001415889-25-004759","document":"form4-02202025_120216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1559569/000141588925004759/form4-02202025_120216.xml","form_type":"4"}},{"id":1258758,"issuer":{"id":6560,"kind":"organization","name":"Equillium, Inc."},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-02-20T00:39:20.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":20770,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023.  All of the other terms of the options remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options vest in twelve equal monthly installments commencing on the grant date of May 26, 2021, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date."}],"balance_after":20770,"derivative":{"exercise_price":0.785,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":20770},"source":{"system":"sec-edgar","filing":"0001415889-25-004759","document":"form4-02202025_120216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1559569/000141588925004759/form4-02202025_120216.xml","form_type":"4"}},{"id":1258757,"issuer":{"id":6560,"kind":"organization","name":"Equillium, Inc."},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-02-20T00:39:20.000Z","date":"2025-02-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023.  All of the other terms of the options remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest in twelve equal monthly installments commencing on the grant date of May 19, 2020, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date."}],"balance_after":0,"derivative":{"exercise_price":2.8,"expiration_date":"2030-05-18","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001415889-25-004759","document":"form4-02202025_120216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1559569/000141588925004759/form4-02202025_120216.xml","form_type":"4"}},{"id":1258756,"issuer":{"id":6560,"kind":"organization","name":"Equillium, Inc."},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-02-20T00:39:20.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":24000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023.  All of the other terms of the options remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest in twelve equal monthly installments commencing on the grant date of May 19, 2020, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date."}],"balance_after":24000,"derivative":{"exercise_price":0.785,"expiration_date":"2030-05-18","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001415889-25-004759","document":"form4-02202025_120216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1559569/000141588925004759/form4-02202025_120216.xml","form_type":"4"}},{"id":1258755,"issuer":{"id":6560,"kind":"organization","name":"Equillium, Inc."},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-02-20T00:39:20.000Z","date":"2025-02-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023.  All of the other terms of the options remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in twelve equal monthly installments commencing on the grant date of June 11, 2019, provided, however, that the option will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date."}],"balance_after":0,"derivative":{"exercise_price":6.01,"expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001415889-25-004759","document":"form4-02202025_120216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1559569/000141588925004759/form4-02202025_120216.xml","form_type":"4"}},{"id":1258754,"issuer":{"id":6560,"kind":"organization","name":"Equillium, Inc."},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-02-20T00:39:20.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023.  All of the other terms of the options remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in twelve equal monthly installments commencing on the grant date of June 11, 2019, provided, however, that the option will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date."}],"balance_after":12000,"derivative":{"exercise_price":0.785,"expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001415889-25-004759","document":"form4-02202025_120216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1559569/000141588925004759/form4-02202025_120216.xml","form_type":"4"}},{"id":1503293,"issuer":{"id":6560,"kind":"organization","name":"Equillium, Inc."},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-23T22:02:45.000Z","date":"2024-05-22","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing on the grant date of May 22, 2024, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date."}],"balance_after":20000,"derivative":{"exercise_price":1.43,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-24-014370","document":"form4-05232024_100533.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1559569/000141588924014370/form4-05232024_100533.xml","form_type":"4"}},{"id":1743586,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:40:39.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":99.66,"underlying":"Common Stock","underlying_shares":17700},"source":{"system":"sec-edgar","filing":"0001104659-23-117094","document":"tm2330435-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117094/tm2330435-13_4seq1.xml","form_type":"4"}},{"id":1743585,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:40:39.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12811,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":110.8,"underlying":"Common Stock","underlying_shares":12811},"source":{"system":"sec-edgar","filing":"0001104659-23-117094","document":"tm2330435-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117094/tm2330435-13_4seq1.xml","form_type":"4"}},{"id":1743584,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:40:39.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":889,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":110.8,"underlying":"Common Stock","underlying_shares":889},"source":{"system":"sec-edgar","filing":"0001104659-23-117094","document":"tm2330435-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117094/tm2330435-13_4seq1.xml","form_type":"4"}},{"id":1743583,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:40:39.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":45293,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":58.74,"underlying":"Common Stock","underlying_shares":45293},"source":{"system":"sec-edgar","filing":"0001104659-23-117094","document":"tm2330435-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117094/tm2330435-13_4seq1.xml","form_type":"4"}},{"id":1743582,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:40:39.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":207,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":58.74,"underlying":"Common Stock","underlying_shares":207},"source":{"system":"sec-edgar","filing":"0001104659-23-117094","document":"tm2330435-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117094/tm2330435-13_4seq1.xml","form_type":"4"}},{"id":1743581,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:40:39.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":38793,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":107.18,"underlying":"Common Stock","underlying_shares":38793},"source":{"system":"sec-edgar","filing":"0001104659-23-117094","document":"tm2330435-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117094/tm2330435-13_4seq1.xml","form_type":"4"}},{"id":1743580,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:40:39.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1207,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":107.18,"underlying":"Common Stock","underlying_shares":1207},"source":{"system":"sec-edgar","filing":"0001104659-23-117094","document":"tm2330435-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117094/tm2330435-13_4seq1.xml","form_type":"4"}},{"id":1743579,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:40:39.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":29865,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":94.29,"underlying":"Common Stock","underlying_shares":29865},"source":{"system":"sec-edgar","filing":"0001104659-23-117094","document":"tm2330435-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117094/tm2330435-13_4seq1.xml","form_type":"4"}},{"id":1743578,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:40:39.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":635,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":94.29,"underlying":"Common Stock","underlying_shares":635},"source":{"system":"sec-edgar","filing":"0001104659-23-117094","document":"tm2330435-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117094/tm2330435-13_4seq1.xml","form_type":"4"}},{"id":1743577,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:40:39.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":31506,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":161.16,"underlying":"Common Stock","underlying_shares":31506},"source":{"system":"sec-edgar","filing":"0001104659-23-117094","document":"tm2330435-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117094/tm2330435-13_4seq1.xml","form_type":"4"}},{"id":1743576,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:40:39.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1044,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":161.16,"underlying":"Common Stock","underlying_shares":1044},"source":{"system":"sec-edgar","filing":"0001104659-23-117094","document":"tm2330435-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117094/tm2330435-13_4seq1.xml","form_type":"4"}},{"id":1743575,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:40:39.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5401,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":266.01,"underlying":"Common Stock","underlying_shares":5401},"source":{"system":"sec-edgar","filing":"0001104659-23-117094","document":"tm2330435-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117094/tm2330435-13_4seq1.xml","form_type":"4"}},{"id":1743574,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:40:39.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":332,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":266.01,"underlying":"Common Stock","underlying_shares":332},"source":{"system":"sec-edgar","filing":"0001104659-23-117094","document":"tm2330435-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117094/tm2330435-13_4seq1.xml","form_type":"4"}},{"id":1743573,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-13T14:40:39.000Z","date":"2023-11-08","kind":"other","planned":false,"acquired":false,"shares":618894,"price":19,"value":11758986.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. (\"Alfasigma\"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the \"Effective Time\"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-117094","document":"tm2330435-13_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117094/tm2330435-13_4seq1.xml","form_type":"4"}},{"id":1880783,"issuer":{"id":6560,"kind":"organization","name":"Equillium, Inc."},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-23T22:04:36.000Z","date":"2023-05-22","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing on the grant date of May 22, 2023, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date."}],"balance_after":20000,"derivative":{"exercise_price":0.65,"expiration_date":"2033-05-22","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-031713","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1559569/000120919123031713/doc4.xml","form_type":"4"}},{"id":2256436,"issuer":{"id":6560,"kind":"organization","name":"Equillium, Inc."},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-25T23:54:32.000Z","date":"2022-05-24","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing on the grant date of May 24, 2022, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date."}],"balance_after":20000,"derivative":{"exercise_price":2.59,"expiration_date":"2032-05-24","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-031994","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1559569/000120919122031994/doc4.xml","form_type":"4"}},{"id":2488449,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T16:05:26.000Z","date":"2021-11-30","kind":"tax_withholding","acquired":false,"shares":3817,"price":17.21,"value":65690.57,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit and performance stock unit awards previously granted to the reporting person."}],"balance_after":618894,"source":{"system":"sec-edgar","filing":"0001104659-21-145908","document":"tm2134452-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921145908/tm2134452-1_4seq1.xml","form_type":"4"}},{"id":2488448,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T16:05:26.000Z","date":"2021-11-30","kind":"grant","acquired":true,"shares":6138,"price":17.21,"value":105634.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock delivered in respect of performance stock unit awards previously granted to the reporting person; such delivery being made pursuant to the Retirement and Consulting Agreement by and between the Issuer and the reporting person, dated December 9, 2020."}],"balance_after":622711,"source":{"system":"sec-edgar","filing":"0001104659-21-145908","document":"tm2134452-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921145908/tm2134452-1_4seq1.xml","form_type":"4"}},{"id":2528440,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-02T16:01:48.000Z","date":"2021-10-29","kind":"tax_withholding","acquired":false,"shares":3817,"price":16.86,"value":64354.62,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit and performance stock unit awards previously granted to the reporting person."}],"balance_after":616573,"source":{"system":"sec-edgar","filing":"0001104659-21-132983","document":"tm2131701-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921132983/tm2131701-1_4seq1.xml","form_type":"4"}},{"id":2528439,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-02T16:01:48.000Z","date":"2021-10-29","kind":"grant","acquired":true,"shares":6138,"price":16.86,"value":103486.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock delivered in respect of performance stock unit awards previously granted to the reporting person; such delivery being made pursuant to the Retirement and Consulting Agreement by and between the Issuer and the reporting person, dated December 9, 2020."}],"balance_after":620390,"source":{"system":"sec-edgar","filing":"0001104659-21-132983","document":"tm2131701-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921132983/tm2131701-1_4seq1.xml","form_type":"4"}},{"id":2551651,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-04T17:02:48.000Z","date":"2021-09-30","kind":"tax_withholding","acquired":false,"shares":3816,"price":14.85,"value":56667.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit and performance stock unit awards previously granted to the reporting person."}],"balance_after":614252,"source":{"system":"sec-edgar","filing":"0001104659-21-122560","document":"tm2129223-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921122560/tm2129223-1_4seq1.xml","form_type":"4"}},{"id":2551650,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-04T17:02:48.000Z","date":"2021-09-30","kind":"grant","acquired":true,"shares":6136,"price":14.85,"value":91119.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock delivered in respect of performance stock unit awards previously granted to the reporting person; such delivery being made pursuant to the Retirement and Consulting Agreement by and between the Issuer and the reporting person, dated December 9, 2020."}],"balance_after":618068,"source":{"system":"sec-edgar","filing":"0001104659-21-122560","document":"tm2129223-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921122560/tm2129223-1_4seq1.xml","form_type":"4"}},{"id":2583330,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-01T19:01:02.000Z","date":"2021-08-31","kind":"tax_withholding","acquired":false,"shares":3817,"price":14.91,"value":56911.47,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit and performance stock unit awards previously granted to the reporting person."}],"balance_after":611932,"source":{"system":"sec-edgar","filing":"0001104659-21-112144","document":"tm2126794-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921112144/tm2126794-1_4seq1.xml","form_type":"4"}},{"id":2583329,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-01T19:01:02.000Z","date":"2021-08-31","kind":"grant","acquired":true,"shares":6138,"price":14.91,"value":91517.58,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock delivered in respect of performance stock unit awards previously granted to the reporting person; such delivery being made pursuant to the Retirement and Consulting Agreement by and between the Issuer and the reporting person, dated December 9, 2020."}],"balance_after":615749,"source":{"system":"sec-edgar","filing":"0001104659-21-112144","document":"tm2126794-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921112144/tm2126794-1_4seq1.xml","form_type":"4"}},{"id":2619841,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-02T19:00:43.000Z","date":"2021-07-30","kind":"tax_withholding","acquired":false,"shares":3817,"price":17.28,"value":65957.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit and performance stock unit awards previously granted to the reporting person."}],"balance_after":609611,"source":{"system":"sec-edgar","filing":"0001104659-21-099031","document":"tm2123867-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921099031/tm2123867-1_4seq1.xml","form_type":"4"}},{"id":2619840,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-02T19:00:43.000Z","date":"2021-07-30","kind":"grant","acquired":true,"shares":6138,"price":17.28,"value":106064.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock delivered in respect of performance stock unit awards previously granted to the reporting person; such delivery being made pursuant to the Retirement and Consulting Agreement by and between the Issuer and the reporting person, dated December 9, 2020."}],"balance_after":613428,"source":{"system":"sec-edgar","filing":"0001104659-21-099031","document":"tm2123867-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921099031/tm2123867-1_4seq1.xml","form_type":"4"}},{"id":2647393,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-01T19:01:27.000Z","date":"2021-06-30","kind":"tax_withholding","acquired":false,"shares":3816,"price":19.97,"value":76205.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit and performance stock unit awards previously granted to the reporting person."}],"balance_after":607290,"source":{"system":"sec-edgar","filing":"0001104659-21-088399","document":"tm2121249-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921088399/tm2121249-1_4seq1.xml","form_type":"4"}},{"id":2647392,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-01T19:01:27.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":6136,"price":19.97,"value":122535.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock delivered in respect of performance stock unit awards previously granted to the reporting person; such delivery being made pursuant to the Retirement and Consulting Agreement by and between the Issuer and the reporting person, dated December 9, 2020."}],"balance_after":611106,"source":{"system":"sec-edgar","filing":"0001104659-21-088399","document":"tm2121249-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921088399/tm2121249-1_4seq1.xml","form_type":"4"}},{"id":2686134,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-02T19:00:43.000Z","date":"2021-05-28","kind":"tax_withholding","acquired":false,"shares":3817,"price":16.63,"value":63476.71,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit and performance stock unit awards previously granted to the reporting person."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes 100,000 shares previously held in a grantor retained annuity trust."}],"balance_after":604970,"source":{"system":"sec-edgar","filing":"0001104659-21-075896","document":"tm2118295d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921075896/tm2118295d1_4.xml","form_type":"4"}},{"id":2686133,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-02T19:00:43.000Z","date":"2021-05-28","kind":"grant","acquired":true,"shares":6138,"price":16.63,"value":102074.94,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock delivered in respect of performance stock unit awards previously granted to the reporting person; such delivery being made pursuant to the Retirement and Consulting Agreement by and between the Issuer and the reporting person, dated December 9, 2020."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes 100,000 shares previously held in a grantor retained annuity trust."}],"balance_after":608787,"source":{"system":"sec-edgar","filing":"0001104659-21-075896","document":"tm2118295d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921075896/tm2118295d1_4.xml","form_type":"4"}},{"id":2690800,"issuer":{"id":6560,"kind":"organization","name":"Equillium, Inc."},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-28T22:18:35.000Z","date":"2021-05-26","kind":"grant","acquired":true,"shares":20770,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest in twelve equal monthly installments commencing on the grant date of May 26, 2021, provided that the options will, in any case, be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2018 Equity Incentive Plan (the \"Plan\")), through such vesting date and will vest in full upon a Change in Control (as defined in the Plan)."}],"balance_after":20770,"derivative":{"exercise_price":6.55,"expiration_date":"2031-05-26","underlying":"Common Stock","underlying_shares":20770},"source":{"system":"sec-edgar","filing":"0001209191-21-036641","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1559569/000120919121036641/doc4.xml","form_type":"4"}},{"id":2729807,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-04T19:00:48.000Z","date":"2021-04-30","kind":"tax_withholding","acquired":false,"shares":3817,"price":19.78,"value":75500.26,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit and performance stock unit awards previously granted to the reporting person."}],"balance_after":502649,"source":{"system":"sec-edgar","filing":"0001104659-21-061181","document":"tm2115142d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921061181/tm2115142d1_4.xml","form_type":"4"}},{"id":2729806,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-04T19:00:48.000Z","date":"2021-04-30","kind":"grant","acquired":true,"shares":6138,"price":19.78,"value":121409.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock delivered in respect of performance stock unit awards previously granted to the reporting person; such delivery being made pursuant to the Retirement and Consulting Agreement by and between the Issuer and the reporting person, dated December 9, 2020."}],"balance_after":506466,"source":{"system":"sec-edgar","filing":"0001104659-21-061181","document":"tm2115142d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921061181/tm2115142d1_4.xml","form_type":"4"}},{"id":2763679,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-01T19:00:48.000Z","date":"2021-03-31","kind":"tax_withholding","acquired":false,"shares":3658,"price":23.08,"value":84426.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit and performance stock unit awards previously granted to the reporting person."}],"balance_after":500328,"source":{"system":"sec-edgar","filing":"0001104659-21-045751","document":"tm2111928d1_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921045751/tm2111928d1_form4.xml","form_type":"4"}},{"id":2763678,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-01T19:00:48.000Z","date":"2021-03-31","kind":"grant","acquired":true,"shares":6136,"price":23.08,"value":141618.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock delivered in respect of performance stock unit awards previously granted to the reporting person; such delivery being made pursuant to the Retirement and Consulting Agreement by and between the Issuer and the reporting person, dated December 9, 2020."}],"balance_after":503986,"source":{"system":"sec-edgar","filing":"0001104659-21-045751","document":"tm2111928d1_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921045751/tm2111928d1_form4.xml","form_type":"4"}},{"id":2819431,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-02T19:01:55.000Z","date":"2021-02-26","kind":"tax_withholding","acquired":false,"shares":2741,"price":21.66,"value":59370.06,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit and performance stock unit awards previously granted to the reporting person."}],"balance_after":497850,"source":{"system":"sec-edgar","filing":"0001104659-21-030902","document":"tm218450-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921030902/tm218450-2_4seq1.xml","form_type":"4"}},{"id":2819430,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-02T19:01:55.000Z","date":"2021-02-26","kind":"grant","acquired":true,"shares":6138,"price":21.66,"value":132949.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock delivered in respect of performance stock unit awards previously granted to the reporting person; such delivery being made pursuant to the Retirement and Consulting Agreement by and between the Issuer and the reporting person, dated December 9, 2020."}],"balance_after":500591,"source":{"system":"sec-edgar","filing":"0001104659-21-030902","document":"tm218450-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921030902/tm218450-2_4seq1.xml","form_type":"4"}},{"id":2885131,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-02T19:00:22.000Z","date":"2021-01-29","kind":"tax_withholding","acquired":false,"shares":2741,"price":35.24,"value":96592.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit and performance stock unit awards previously granted to the reporting person."}],"balance_after":494453,"source":{"system":"sec-edgar","filing":"0001104659-21-011073","document":"tm215092-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921011073/tm215092-1_4seq1.xml","form_type":"4"}},{"id":2885130,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-02T19:00:22.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":6138,"price":35.24,"value":216303.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock delivered in respect of performance stock unit awards previously granted to the reporting person; such delivery being made pursuant to the Retirement and Consulting Agreement by and between the Issuer and the reporting person, dated December 9, 2020."}],"balance_after":497194,"source":{"system":"sec-edgar","filing":"0001104659-21-011073","document":"tm215092-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921011073/tm215092-1_4seq1.xml","form_type":"4"}},{"id":2919930,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-05T19:01:36.000Z","date":"2021-01-01","kind":"tax_withholding","acquired":false,"shares":632,"price":24.7,"value":15610.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person."}],"balance_after":491056,"source":{"system":"sec-edgar","filing":"0001104659-21-001125","document":"tm211606-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921001125/tm211606-7_4seq1.xml","form_type":"4"}},{"id":2919929,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-05T19:01:36.000Z","date":"2020-12-31","kind":"tax_withholding","acquired":false,"shares":25065,"price":24.7,"value":619105.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit and performance stock unit awards previously granted to the reporting person"}],"balance_after":491688,"source":{"system":"sec-edgar","filing":"0001104659-21-001125","document":"tm211606-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921001125/tm211606-7_4seq1.xml","form_type":"4"}},{"id":2919928,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-05T19:01:36.000Z","date":"2020-12-31","kind":"grant","acquired":true,"shares":41236,"price":24.7,"value":1018529.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock delivered in respect of performance stock unit awards previously granted to the reporting person; such delivery being made pursuant to the Retirement and Consulting Agreement by and between the Issuer and the reporting person, dated December 9, 2020."}],"balance_after":516753,"source":{"system":"sec-edgar","filing":"0001104659-21-001125","document":"tm211606-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921001125/tm211606-7_4seq1.xml","form_type":"4"}},{"id":3012870,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-10-05T19:01:46.000Z","date":"2020-10-01","kind":"tax_withholding","acquired":false,"shares":772,"price":42.08,"value":32485.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person."}],"balance_after":475517,"source":{"system":"sec-edgar","filing":"0001104659-20-112319","document":"tm2032461d4_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465920112319/tm2032461d4_4.xml","form_type":"4"}},{"id":3088514,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-07-06T19:02:39.000Z","date":"2020-07-01","kind":"tax_withholding","acquired":false,"shares":772,"price":46.52,"value":35913.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person."}],"balance_after":476289,"source":{"system":"sec-edgar","filing":"0001104659-20-081441","document":"tm20240737_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465920081441/tm20240737_4.xml","form_type":"4"}},{"id":3138696,"issuer":{"id":6560,"kind":"organization","name":"Equillium, Inc."},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-21T20:30:21.000Z","date":"2020-05-19","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in twelve equal monthly installments commencing on the grant date of May 19, 2020, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date."}],"balance_after":24000,"derivative":{"exercise_price":2.8,"expiration_date":"2030-05-19","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-20-031275","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1559569/000120919120031275/doc4.xml","form_type":"4"}},{"id":3182788,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-04-03T19:06:53.000Z","date":"2020-04-01","kind":"tax_withholding","acquired":false,"shares":568,"price":58.4,"value":33171.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person."}],"balance_after":477061,"source":{"system":"sec-edgar","filing":"0001104659-20-043289","document":"tm2014981d7_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465920043289/tm2014981d7_4.xml","form_type":"4"}},{"id":3301198,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2020-01-27T19:07:47.000Z","date":"2020-01-23","kind":"grant","acquired":true,"shares":17700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2020."}],"balance_after":17700,"derivative":{"exercise_price":99.66,"expiration_date":"2030-01-23","underlying":"Common Stock","underlying_shares":17700},"source":{"system":"sec-edgar","filing":"0001104659-20-007268","document":"tm205922d9_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465920007268/tm205922d9_4.xml","form_type":"4"}},{"id":3301197,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-01-27T19:07:47.000Z","date":"2020-01-23","kind":"grant","acquired":true,"shares":10800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2020."}],"balance_after":477629,"source":{"system":"sec-edgar","filing":"0001104659-20-007268","document":"tm205922d9_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465920007268/tm205922d9_4.xml","form_type":"4"}},{"id":3322325,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2020-01-03T19:00:52.000Z","date":"2019-12-31","kind":"exercise","acquired":false,"shares":100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested and exercisable."}],"balance_after":30084,"derivative":{"exercise_price":21.5,"expiration_date":"2022-11-16","underlying":"Common Stock","underlying_shares":100},"source":{"system":"sec-edgar","filing":"0001104659-20-001086","document":"tm201209d3_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465920001086/tm201209d3_4.xml","form_type":"4"}},{"id":3322324,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-01-03T19:00:52.000Z","date":"2020-01-01","kind":"tax_withholding","acquired":false,"shares":1166,"price":123.92,"value":144490.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock awards previously granted to the reporting person."}],"balance_after":466829,"source":{"system":"sec-edgar","filing":"0001104659-20-001086","document":"tm201209d3_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465920001086/tm201209d3_4.xml","form_type":"4"}},{"id":3322323,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-01-03T19:00:52.000Z","date":"2019-12-31","kind":"tax_withholding","acquired":false,"shares":1131,"price":123.92,"value":140153.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person."}],"balance_after":467995,"source":{"system":"sec-edgar","filing":"0001104659-20-001086","document":"tm201209d3_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465920001086/tm201209d3_4.xml","form_type":"4"}},{"id":3322322,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-01-03T19:00:52.000Z","date":"2019-12-31","kind":"sale","acquired":false,"shares":100,"price":125,"value":12500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":469126,"source":{"system":"sec-edgar","filing":"0001104659-20-001086","document":"tm201209d3_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465920001086/tm201209d3_4.xml","form_type":"4"}},{"id":3322321,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-01-03T19:00:52.000Z","date":"2019-12-31","kind":"exercise","acquired":true,"shares":100,"price":21.5,"value":2150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":469226,"source":{"system":"sec-edgar","filing":"0001104659-20-001086","document":"tm201209d3_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465920001086/tm201209d3_4.xml","form_type":"4"}},{"id":3329669,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2019-12-30T19:00:56.000Z","date":"2019-12-26","kind":"exercise","acquired":false,"shares":417,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is fully vested and exercisable."}],"balance_after":30184,"derivative":{"exercise_price":21.5,"expiration_date":"2022-11-16","underlying":"Common Stock","underlying_shares":417},"source":{"system":"sec-edgar","filing":"0001104659-19-076863","document":"tm1928364d2_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465919076863/tm1928364d2_4.xml","form_type":"4"}},{"id":3329668,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-12-30T19:00:56.000Z","date":"2019-12-26","kind":"sale","acquired":false,"shares":417,"price":125,"value":52125.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":469126,"source":{"system":"sec-edgar","filing":"0001104659-19-076863","document":"tm1928364d2_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465919076863/tm1928364d2_4.xml","form_type":"4"}},{"id":3329667,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-12-30T19:00:56.000Z","date":"2019-12-26","kind":"exercise","acquired":true,"shares":417,"price":21.5,"value":8965.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":469543,"source":{"system":"sec-edgar","filing":"0001104659-19-076863","document":"tm1928364d2_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465919076863/tm1928364d2_4.xml","form_type":"4"}},{"id":3357197,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2019-11-27T19:00:20.000Z","date":"2019-11-26","kind":"exercise","acquired":false,"shares":15557,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested and exercisable."}],"balance_after":30601,"derivative":{"exercise_price":21.5,"expiration_date":"2022-11-16","underlying":"Common Stock","underlying_shares":15557},"source":{"system":"sec-edgar","filing":"0001104659-19-068397","document":"tm1924027d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465919068397/tm1924027d1_4.xml","form_type":"4"}},{"id":3357196,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2019-11-27T19:00:20.000Z","date":"2019-11-26","kind":"exercise","acquired":false,"shares":19880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":8.6667,"expiration_date":"2021-10-13","underlying":"Common Stock","underlying_shares":19880},"source":{"system":"sec-edgar","filing":"0001104659-19-068397","document":"tm1924027d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465919068397/tm1924027d1_4.xml","form_type":"4"}},{"id":3357195,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2019-11-27T19:00:20.000Z","date":"2019-11-25","kind":"exercise","acquired":false,"shares":14524,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested and exercisable."}],"balance_after":19880,"derivative":{"exercise_price":8.6667,"expiration_date":"2021-10-13","underlying":"Common Stock","underlying_shares":14524},"source":{"system":"sec-edgar","filing":"0001104659-19-068397","document":"tm1924027d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465919068397/tm1924027d1_4.xml","form_type":"4"}},{"id":3357194,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2019-11-27T19:00:20.000Z","date":"2019-11-25","kind":"exercise","acquired":false,"shares":39,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":8.6667,"expiration_date":"2020-08-16","underlying":"Common Stock","underlying_shares":39},"source":{"system":"sec-edgar","filing":"0001104659-19-068397","document":"tm1924027d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465919068397/tm1924027d1_4.xml","form_type":"4"}},{"id":3357193,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-11-27T19:00:20.000Z","date":"2019-11-26","kind":"sale","acquired":false,"shares":35437,"price":100,"value":3543700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":469126,"source":{"system":"sec-edgar","filing":"0001104659-19-068397","document":"tm1924027d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465919068397/tm1924027d1_4.xml","form_type":"4"}},{"id":3357192,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-11-27T19:00:20.000Z","date":"2019-11-26","kind":"exercise","acquired":true,"shares":15557,"price":21.5,"value":334475.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":504563,"source":{"system":"sec-edgar","filing":"0001104659-19-068397","document":"tm1924027d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465919068397/tm1924027d1_4.xml","form_type":"4"}},{"id":3357191,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-11-27T19:00:20.000Z","date":"2019-11-26","kind":"exercise","acquired":true,"shares":19880,"price":8.6667,"value":172293.996,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":489006,"source":{"system":"sec-edgar","filing":"0001104659-19-068397","document":"tm1924027d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465919068397/tm1924027d1_4.xml","form_type":"4"}},{"id":3357190,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-11-27T19:00:20.000Z","date":"2019-11-25","kind":"sale","acquired":false,"shares":14563,"price":100,"value":1456300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":469126,"source":{"system":"sec-edgar","filing":"0001104659-19-068397","document":"tm1924027d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465919068397/tm1924027d1_4.xml","form_type":"4"}},{"id":3357189,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-11-27T19:00:20.000Z","date":"2019-11-25","kind":"exercise","acquired":true,"shares":14524,"price":8.6667,"value":125875.1508,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":483689,"source":{"system":"sec-edgar","filing":"0001104659-19-068397","document":"tm1924027d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465919068397/tm1924027d1_4.xml","form_type":"4"}},{"id":3357188,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-11-27T19:00:20.000Z","date":"2019-11-25","kind":"exercise","acquired":true,"shares":39,"price":8.6667,"value":338.0013,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":469165,"source":{"system":"sec-edgar","filing":"0001104659-19-068397","document":"tm1924027d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465919068397/tm1924027d1_4.xml","form_type":"4"}},{"id":3398294,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-10-03T19:02:07.000Z","date":"2019-10-01","kind":"tax_withholding","acquired":false,"shares":1547,"price":65.87,"value":101900.89,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock awards previously granted to the reporting person."}],"balance_after":469126,"source":{"system":"sec-edgar","filing":"0001144204-19-047220","document":"tv530561_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420419047220/tv530561_4.xml","form_type":"4"}},{"id":3467680,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-07-03T17:00:41.000Z","date":"2019-07-01","kind":"tax_withholding","acquired":false,"shares":1548,"price":79.17,"value":122555.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock awards previously granted to the reporting person."}],"balance_after":470673,"source":{"system":"sec-edgar","filing":"0001144204-19-033811","document":"tv524730_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420419033811/tv524730_form4.xml","form_type":"4"}},{"id":3490899,"issuer":{"id":6560,"kind":"organization","name":"Equillium, Inc."},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-13T20:41:19.000Z","date":"2019-06-11","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in twelve equal monthly installments commencing on the grant date of June 11, 2019, provided, however, that the option will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date."}],"balance_after":12000,"derivative":{"exercise_price":6.01,"expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-19-036807","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1559569/000120919119036807/doc4.xml","form_type":"4"}},{"id":3564216,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-04-03T19:00:25.000Z","date":"2019-04-01","kind":"tax_withholding","acquired":false,"shares":1547,"price":111.5,"value":172490.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock awards previously granted to the reporting person."}],"balance_after":472221,"source":{"system":"sec-edgar","filing":"0001144204-19-018074","document":"tv517179_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420419018074/tv517179_4.xml","form_type":"4"}},{"id":3691644,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2019-01-18T19:03:40.000Z","date":"2019-01-16","kind":"grant","acquired":true,"shares":13700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2019."}],"balance_after":13700,"derivative":{"exercise_price":110.8,"expiration_date":"2029-01-16","underlying":"Common Stock","underlying_shares":13700},"source":{"system":"sec-edgar","filing":"0001144204-19-002141","document":"tv511182_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420419002141/tv511182_4.xml","form_type":"4"}},{"id":3691643,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-01-18T19:03:40.000Z","date":"2019-01-16","kind":"grant","acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2019."}],"balance_after":573768,"source":{"system":"sec-edgar","filing":"0001144204-19-002141","document":"tv511182_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420419002141/tv511182_4.xml","form_type":"4"}},{"id":3708149,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-01-03T19:03:36.000Z","date":"2019-01-01","kind":"tax_withholding","acquired":false,"shares":1537,"price":100.79,"value":154914.23,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock withheld to satisfy taxes associated with the vesting of restricted stock."}],"balance_after":565268,"source":{"system":"sec-edgar","filing":"0001144204-19-000501","document":"tv510192_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420419000501/tv510192_form4.xml","form_type":"4"}},{"id":3760730,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2018-11-16T19:00:24.000Z","date":"2018-11-16","kind":"exercise","acquired":false,"shares":27606,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person for financial and tax planning purposes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option is fully vested and exercisable."}],"balance_after":39,"derivative":{"exercise_price":8.6667,"expiration_date":"2020-08-16","underlying":"Common Stock","underlying_shares":27606},"source":{"system":"sec-edgar","filing":"0001144204-18-060579","document":"tv507484_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420418060579/tv507484_4.xml","form_type":"4"}},{"id":3760729,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2018-11-16T19:00:24.000Z","date":"2018-11-15","kind":"exercise","acquired":false,"shares":22394,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person for financial and tax planning purposes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option is fully vested and exercisable."}],"balance_after":27645,"derivative":{"exercise_price":8.6667,"expiration_date":"2020-08-16","underlying":"Common Stock","underlying_shares":22394},"source":{"system":"sec-edgar","filing":"0001144204-18-060579","document":"tv507484_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420418060579/tv507484_4.xml","form_type":"4"}},{"id":3760728,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-16T19:00:24.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":1988,"price":103.286,"value":205332.568,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person for financial and tax planning purposes."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.025 to $103.57, inclusive."}],"balance_after":566805,"source":{"system":"sec-edgar","filing":"0001144204-18-060579","document":"tv507484_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420418060579/tv507484_4.xml","form_type":"4"}},{"id":3760727,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-16T19:00:24.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":7839,"price":102.6118,"value":804373.9002,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person for financial and tax planning purposes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.025 to $103.02, inclusive."}],"balance_after":568793,"source":{"system":"sec-edgar","filing":"0001144204-18-060579","document":"tv507484_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420418060579/tv507484_4.xml","form_type":"4"}},{"id":3760726,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-16T19:00:24.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":7949,"price":101.4828,"value":806686.7772,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person for financial and tax planning purposes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.00 to $101.955, inclusive."}],"balance_after":576632,"source":{"system":"sec-edgar","filing":"0001144204-18-060579","document":"tv507484_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420418060579/tv507484_4.xml","form_type":"4"}},{"id":3760725,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-16T19:00:24.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":9830,"price":100.38,"value":986735.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person for financial and tax planning purposes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4."}],"balance_after":584581,"source":{"system":"sec-edgar","filing":"0001144204-18-060579","document":"tv507484_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420418060579/tv507484_4.xml","form_type":"4"}},{"id":3760724,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-16T19:00:24.000Z","date":"2018-11-16","kind":"exercise","acquired":true,"shares":27606,"price":8.6667,"value":239252.9202,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person for financial and tax planning purposes."}],"balance_after":594411,"source":{"system":"sec-edgar","filing":"0001144204-18-060579","document":"tv507484_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420418060579/tv507484_4.xml","form_type":"4"}},{"id":3760723,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-16T19:00:24.000Z","date":"2018-11-15","kind":"sale","acquired":false,"shares":3521,"price":101.1327,"value":356088.2367,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person for financial and tax planning purposes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.00 to $101.285, inclusive."}],"balance_after":566805,"source":{"system":"sec-edgar","filing":"0001144204-18-060579","document":"tv507484_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420418060579/tv507484_4.xml","form_type":"4"}},{"id":3760722,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-16T19:00:24.000Z","date":"2018-11-15","kind":"sale","acquired":false,"shares":18873,"price":100.3813,"value":1894496.2749,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person for financial and tax planning purposes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4."}],"balance_after":570326,"source":{"system":"sec-edgar","filing":"0001144204-18-060579","document":"tv507484_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420418060579/tv507484_4.xml","form_type":"4"}},{"id":3760721,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-16T19:00:24.000Z","date":"2018-11-15","kind":"exercise","acquired":true,"shares":22394,"price":8.6667,"value":194082.0798,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person for financial and tax planning purposes."}],"balance_after":589199,"source":{"system":"sec-edgar","filing":"0001144204-18-060579","document":"tv507484_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420418060579/tv507484_4.xml","form_type":"4"}},{"id":3798291,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-10-03T19:00:25.000Z","date":"2018-10-01","kind":"tax_withholding","acquired":false,"shares":2049,"price":126.46,"value":259116.54,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock withheld to satisfy taxes associated with the vesting of restricted stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the amount of securities beneficially owned following the reported transactions is provided as of the date of this Form 4."}],"balance_after":566805,"source":{"system":"sec-edgar","filing":"0001144204-18-052403","document":"tv503771_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420418052403/tv503771_4.xml","form_type":"4"}},{"id":3798290,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-10-03T19:00:25.000Z","date":"2018-07-01","kind":"tax_withholding","acquired":false,"shares":2051,"price":83.91,"value":172099.41,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock withheld to satisfy taxes associated with the vesting of restricted stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the amount of securities beneficially owned following the reported transactions is provided as of the date of this Form 4."}],"balance_after":566805,"source":{"system":"sec-edgar","filing":"0001144204-18-052403","document":"tv503771_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420418052403/tv503771_4.xml","form_type":"4"}},{"id":3798289,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-10-03T19:00:25.000Z","date":"2018-04-01","kind":"tax_withholding","acquired":false,"shares":2050,"price":61.52,"value":126116.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock withheld to satisfy taxes associated with the vesting of restricted stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the amount of securities beneficially owned following the reported transactions is provided as of the date of this Form 4."}],"balance_after":566805,"source":{"system":"sec-edgar","filing":"0001144204-18-052403","document":"tv503771_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420418052403/tv503771_4.xml","form_type":"4"}},{"id":3798288,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-10-03T19:00:25.000Z","date":"2018-01-01","kind":"tax_withholding","acquired":false,"shares":3609,"price":58.42,"value":210837.78,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock withheld to satisfy taxes associated with the vesting of restricted stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the amount of securities beneficially owned following the reported transactions is provided as of the date of this Form 4."}],"balance_after":566805,"source":{"system":"sec-edgar","filing":"0001144204-18-052403","document":"tv503771_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420418052403/tv503771_4.xml","form_type":"4"}},{"id":3966908,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2018-04-09T19:36:47.000Z","date":"2018-04-09","kind":"purchase","acquired":true,"shares":7812,"price":64,"value":499968.0,"ownership":{"direct":true},"balance_after":576564,"source":{"system":"sec-edgar","filing":"0001144204-18-019836","document":"tv490675_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420418019836/tv490675_form4.xml","form_type":"4"}},{"id":4039917,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":43110,"kind":"person","name":"Pruzanski Mark","position":1,"cik":"0001559569","reported_name":"Pruzanski Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Options to Purchase Common Stock","published_at":"2018-02-22T21:02:12.000Z","date":"2018-02-05","kind":"grant","acquired":true,"shares":45500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares of common stock underlying this option will vest on January 1, 2019, subject to the terms and conditions of the award and the 2012 Plan. The remainder of the shares of common stock underlying this option will vest pro rata on a monthly basis after the initial vesting date through January 1, 2022 (representing the vesting on each such vesting date of approximately 2.0833% of the shares of common stock initially underlying this option), subject to the terms and conditions of the award and the 2012 Plan."}],"balance_after":45500,"derivative":{"exercise_price":58.74,"expiration_date":"2028-02-05","underlying":"Common Stock","underlying_shares":45500},"source":{"system":"sec-edgar","filing":"0001144204-18-010361","document":"tv486825_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420418010361/tv486825_4.xml","form_type":"4"}}],"next_cursor":"2018-02-22T21:02:12.000000Z,4039917"}